RECURRENT EPITHELIAL OVARIAN, FALLOPIAN OR PERITONEAL CARCINOMA

Clinical trials for RECURRENT EPITHELIAL OVARIAN, FALLOPIAN OR PERITONEAL CARCINOMA explained in plain language.

Never miss a new study

Get alerted when new RECURRENT EPITHELIAL OVARIAN, FALLOPIAN OR PERITONEAL CARCINOMA trials appear

Sign up with your email to follow new studies for RECURRENT EPITHELIAL OVARIAN, FALLOPIAN OR PERITONEAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

New targeted therapy shows promise for Tough-to-Treat ovarian cancer

Disease control Ongoing

This study tests a drug called mirvetuximab soravtansine in people whose ovarian cancer has come back and has high levels of a protein called folate receptor alpha. The drug delivers a toxin directly to cancer cells. About 136 participants will either get this drug or standard ch…

Matched conditions: RECURRENT EPITHELIAL OVARIAN, FALLOPIAN OR PERITONEAL CARCINOMA

Phase: PHASE2 • Sponsor: AGO Research GmbH • Aim: Disease control

Last updated May 22, 2026 13:52 UTC

RECURRENT EPITHELIAL OVARIAN, FALLOPIAN OR PERITONEAL CARCINOMA

Get alerted when new RECURRENT EPITHELIAL OVARIAN, FALLOPIAN OR PERITONEAL CARCINOMA trials appear

New targeted therapy shows promise for Tough-to-Treat ovarian cancer